Nanotherapeutics Closes Final Round of Financing for Completion of New Advanced Development and Manufacturing Facility
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.
The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.
About White Oak Global Advisors, LLC
White Oak Global Advisors, LLC, is an SEC-registered investment adviser that directly originates private debt financings to middle market companies to support growth initiatives. White Oak's product suite includes asset-based secured term loans and credit facilities, cash flow based term loans, unitranche facilities, rescue and debtor-in-possession (DIP) financings, in/out of court restructurings, acquisition and capital expenditure facilities and other structured finance instruments. With over $1.7 billion of invested and committed capital,1 White Oak has made over 75 direct debt investments in companies with enterprise values between $50MM and $1BN across a diverse range of industries and sectors. Headquartered in San Francisco, White Oak has additional offices in New York City, Dallas and Denver. To learn more about White Oak Global Advisors, LLC, visit www.whiteoaksf.com
About Nanotherapeutics, Inc.
Nanotherapeutics develops, manufactures, and distributes biodefense, infectious disease and influenza products, globally. The Company has expertise in preclinical and clinical development, formulation optimization, and cGMP manufacturing of biopharmaceutical products and medical devices. The Company's proprietary platform technologies can be used with all drug types, ranging from small molecules, to proteins and vaccines. For more information, visit the Company website at www.nanotherapeutics.com.
1 Calculated as of December 31, 2014 and includes Regulatory Assets under Management in addition to the uncalled capital commitments of the separate accounts managed by White Oak